Approval · Notice of Compliance 7319 · 2005
APO-SUMATRIPTAN: Notice of Compliance 7319
Issued August 24, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7319
- Date
- August 24, 2005
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX (Glaxo Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-SUMATRIPTAN | 02268388 | Marketed |
| APO-SUMATRIPTAN | 02268396 | Marketed |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB